Italian clinicians report the results of a study on the use of a new molecule, bempedoic acid, which has lipid-lowering properties but does not carry the risk of developing immune-mediated necrotising myopathy (IMNM):
- 10 patients with IMNMÂ positive for anti-HMGCR autoantibodies were included in an open-label study.
- All had received prednisone and immunosuppressants to control their IMNM.
- treatment with bempedoic acid was initiated due to the need to effectively treat their dyslipidaemia,
- after 6 months of treatment, IMNMÂ biomarkers (CPK, anti-HMGCR antibodies) indicated ongoing remission, as did the mean LDL cholesterol value.
This new molecule could be an interesting alternative for people at risk of developing IMNM.
